{"schema_version":"secwatch.filing_event.v1","accession":"0001818382-25-000030","form_type":"8-K","ticker":"HUMA","cik":"0001818382","company_name":"Humacyte, Inc.","filed_at":"2025-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.040548+00:00","generated_at":"2026-05-24T03:13:44.340050+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Humacyte posts Q4 net loss of $20.9M; Symvess commercial launch underway after FDA approval","bullets":["Net loss Q4 2024 $20.9M vs $25.1M Q4 2023; full year net loss $148.7M vs $110.8M.","Cash $95.3M at Dec 31, 2024; raised $46.6M net in March 2025 public offering.","FDA approved Symvess Dec 19, 2024 for extremity vascular trauma; first commercial shipments to two Level 1 trauma centers in Feb 2025.","34 hospitals started VAC approval process; 3 approved; first sales recorded.","R&D expenses $88.6M in 2024 (up 16% YoY); no revenue in period."],"urls":{"canonical":"https://secwatch.observer/filing/0001818382-25-000030","json":"https://secwatch.observer/filing/0001818382-25-000030.json","markdown":"https://secwatch.observer/filing/0001818382-25-000030.md","text":"https://secwatch.observer/filing/0001818382-25-000030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818382/000181838225000030/0001818382-25-000030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818382/000181838225000030/huma-20250328.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T03:13:44.340050+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}